Pharming Group N.V. (PHAR)
| Market Cap | 9.03B |
| Revenue (ttm) | 189.91M |
| Net Income (ttm) | 40.67M |
| Shares Out | 638.06M |
| EPS (ttm) | 0.61 |
| PE Ratio | 23.34 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $14.16 |
| Previous Close | $14.60 |
| Change ($) | -0.44 |
| Change (%) | -3.01% |
| Day's Open | 14.43 |
| Day's Range | 13.97 - 14.50 |
| Day's Volume | 7,772 |
| 52-Week Range | 13.97 - 16.70 |
News
Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ("ADSs") have been admitted for listing on the Nasdaq Global Market ("Nasdaq") u...
Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unm...
Pharming Group N.V. has filed to go public with an IPO on the NASDAQ.
About PHAR
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as ... [Read more...]
| Industry Research and Development in Biotechnology | Founded 1988 |
| CEO Sijmen de Vries | Employees 258 |
| Stock Exchange NASDAQ | Ticker Symbol PHAR |
Financial Performance
In 2019, Pharming Group's revenue was 169.02 million, an increase of 25.08% compared to the previous year's 135.13 million. Earnings were 36.20 million, an increase of 44.82%.